# Effect of Dexamethason on Postimplantation Syndrome After EVAR

Study · id `cardio:ct-nct06044480` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06044480](<https://clinicaltrials.gov/study/NCT06044480>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06044480

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 158 participants.

## Technical summary

Registry record NCT06044480. Randomized; triple masking; primary purpose prevention. Start 2023-11-01 (anticipated); primary completion 2025-05-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 158 participants (planned count; ClinicalTrials.gov record NCT06044480, source copy `cardio:ctgov-nct06044480-2023-09-21`, retrieved 2026-11-18)
- Planned start: 2023-11-01 (anticipated) (ClinicalTrials.gov record NCT06044480, source copy `cardio:ctgov-nct06044480-2023-09-21`, retrieved 2026-11-18)
- Primary completion: 2025-05-31 (anticipated) (ClinicalTrials.gov record NCT06044480, source copy `cardio:ctgov-nct06044480-2023-09-21`, retrieved 2026-11-18)
- Completion: 2026-05-31 (anticipated) (ClinicalTrials.gov record NCT06044480, source copy `cardio:ctgov-nct06044480-2023-09-21`, retrieved 2026-11-18)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06044480-2023-09-21`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effect of Dexamethason on Postimplantation Syndrome After EVAR
- Acronym: DEPOS
- Condition: Aneurysm Abdominal
- Condition: Endovascular Aneurysm Repair
- Condition: Postimplantation Syndrome
- Condition: Dexamethasone
- Intervention (Drug): Dexamethasone
- Intervention (Other): Placebo
- Lead sponsor: Centro Hospitalar de Lisboa Central
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Abdominal aortic aneurysm (`cardio:abdominal-aortic-aneurysm`)

## Provenance

Content hash: 65edc69eebea976b21e4a0c3c48827a3fd1df47037c61aa10d44ad85afabccfa
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
